Therefore, we analyzed progression tissue microarrays (TMAs) including normal breast tissue, ductal carcinoma in situ (DCIS), 3 groups of invasive ductal carcinomas (ER positive; HER2 positive; or TN) as well as invasive lobular carcinoma (ILC) using IHC. This evidence concerns the gene ERBB2 and invasive ductal breast carcinoma.